| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8650963 | American Heart Journal | 2018 | 24 Pages |
Abstract
In this pilot trial, low-dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose-dependent benefit on post-MI remodeling that may warrant further study.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Noel M. MD, PhD, Mary C. DeVoe, Janet Choi, Darren Dahly, Theodore Murphy, Ernest Spitzer, Robert Van Geuns, Michael M. Maher, David Tuite, David M. Kerins, Mohammed T. Ali, Imtiaz Kalyar, Eoin F. Fahy, Wisam Khider, Peter Kelly, Peter P. Kearney,